Myriad Genetics Inc. inked a deal with pharmaceutical giant Pfizer Inc. to promote Myriad's BRACAnalysis CDx test to identify breast cancer patients that would benefit from treatment with talazoparib, Pfizer's investigational poly-ADP ribose polymerase inhibitor drug.
Under the agreement, both companies will remain responsible for marketing their own products, but will collaborate on certain activities to...